Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.
FDA clears Novo's liraglutide for obesity; doctors' views vary on Express Scripts' hep.-C plan; Janssen, Gilead advance plans for HIV drugs.
The number of new HIV cases has held steady since the 1990s. Researchers note it is progress of a sort, but that driving numbers down requires one basic step: testing, testing, testing.
The deal will cap the monthly price some patients may pay for medications such as Atripla.
Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.
Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
The GlaxoSmithKline-Pfizer-Shionogi joint venture scored an FDA approval in August.
The Kaiser Family Foundation's just-launched website, funded by Gilead, addresses healthcare reform from a distinct perspective.
Adding Epzicom to Tivicay in a once-daily cocktail could further boost GSK's HIV franchise, and possibly chip away at Atripla's dominance.
Gilead's Striblid faces hurdle in Germany, Boehringer and Roche team up for companion diagnostic effort and Wisconsin hospital system says no to samples
CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany
The GSK-Pfizer-Shionogi daily HIV medication gets the regulatory all-clear. The approval could put BMS/Gilead's best-selling daily med Atripla on the defensive.
A two-year study shows Gilead's Quad pill outpaces an older combination drug over two years, and GSK is seeking to expand its oncology presence.
Messaging around HIV testing now mixes individual concerns with community protection. Recent efforts, like those of the CDC and Greater than AIDS, try to make getting tested an empowering act.
Pharma pared back its ad spend in 2012, a baby born HIV-positive is virus-free two-and-a-half years later, and Boston Children's Hospital is making its own apps.
As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.
The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.